{
    "nct_id": "NCT03751124",
    "official_title": "An International Phase 3 Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids",
    "inclusion_criteria": "1. Completed the open-label extension study (MVT-601-3003).\n2. Is a responder: Has a menstrual blood loss of < 80 mL AND at least a 50% reduction from the parent study Baseline based on the results of the alkaline hematin testing performed on the feminine products returned at the Week 48 visit of the extension study.\n3. Is not expected to undergo gynecological surgery or ablation procedures for uterine fibroids within the study period\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 51 Years",
    "exclusion_criteria": "1. Has undergone myomectomy, ultrasound-guided laparoscopic radiofrequency ablation, or any other surgical procedure for fibroids, uterine artery embolization, magnetic resonance guided focused ultrasound for fibroids, or endometrial ablation for abnormal uterine bleeding at any time during the Parent study or extension study.\n2. Has a weight that exceeds the weight limit of the dual-energy x-ray absorptiometry (DXA) scanner\n3. Has developed any contraindication to treatment with estradiol or norethindrone acetate\n4. Is currently pregnant or lactating, or intends to become pregnant during the study period\n5. Met a withdrawal criterion in the open-label extension (OLE) study.",
    "miscellaneous_criteria": ""
}